Alzamend Neuro Inc (NASDAQ:ALZN) — Market Cap & Net Worth
Market Cap & Net Worth: Alzamend Neuro Inc (ALZN)
Alzamend Neuro Inc (NASDAQ:ALZN) has a market capitalization of $3.43 Million ($3.43 Million) as of May 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #29005 globally and #5691 in its home market, demonstrating a -0.88% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Alzamend Neuro Inc's stock price $1.12 by its total outstanding shares 3804741 (3.80 Million). Analyse ALZN operating cash flow to see how efficiently the company converts income to cash.
Alzamend Neuro Inc Market Cap History: 2021 to 2026
Alzamend Neuro Inc's market capitalization history from 2021 to 2026. Data shows change from $1.08 Billion to $4.26 Million (-78.50% CAGR).
Index Memberships
Alzamend Neuro Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.41 Trillion | 0.00% | #863 of 976 |
|
NASDAQ Composite
IXIC
|
$38.77 Trillion | 0.00% | #2760 of 3165 |
Weight: Alzamend Neuro Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Alzamend Neuro Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Alzamend Neuro Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of ALZN by Market Capitalization
Companies near Alzamend Neuro Inc in the global market cap rankings as of May 4, 2026.
Key companies related to Alzamend Neuro Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Alzamend Neuro Inc Historical Marketcap From 2021 to 2026
Between 2021 and today, Alzamend Neuro Inc's market cap moved from $1.08 Billion to $ 4.26 Million, with a yearly change of -78.50%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $4.26 Million | -38.46% |
| 2025 | $6.92 Million | +56.90% |
| 2024 | $4.41 Million | -86.97% |
| 2023 | $33.86 Million | -89.50% |
| 2022 | $322.45 Million | -70.26% |
| 2021 | $1.08 Billion | -- |
End of Day Market Cap According to Different Sources
On May 4th, 2026 the market cap of Alzamend Neuro Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $3.43 Million USD |
| MoneyControl | $3.43 Million USD |
| MarketWatch | $3.43 Million USD |
| marketcap.company | $3.43 Million USD |
| Reuters | $3.43 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Alzamend Neuro Inc
Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. Its pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neur… Read more